公开(公告)号：US12241065B2

公开(公告)日：2025-03-04

申请号：US16961578

申请日：2019-01-11

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. Olson ,  Angela M. Cacace ,  Jere E. Meredith, Jr. ,  Nino Devidze ,  James K. Loy ,  Carl J. Baldick ,  Annapurna Pendri ,  Ivar M. McDonald ,  Peter Hagedorn ,  Marianne Lerbech Jensen

IPC: C12N15/113 ,  A61K9/00 ,  A61K31/7088 ,  A61K39/395

Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.

公开(公告)号：US11713316B2

公开(公告)日：2023-08-01

申请号：US17164009

申请日：2021-02-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Upender Velaparthi ,  Louis S. Chupak ,  Chetan Padmakar Darne ,  Min Ding ,  Robert G. Gentles ,  Yazhong Huang ,  Manjunatha Narayana Rao Kamble ,  Scott W. Martin ,  Raju Mannoori ,  Ivar M. McDonald ,  Richard E. Olson ,  Hasibur Rahaman ,  Prasada Rao Jalagam ,  Saumya Roy ,  Gopikishan Tonukunuru ,  Sivasudar Velaiah ,  Jayakumar Sankara Warrier ,  Xiaofan Zheng ,  John S. Tokarski ,  Bireshwar Dasgupta ,  Kotha Rathnakar Reddy ,  Thiruvenkadam Raja

IPC: C07D403/04 ,  C07D471/04 ,  C07D487/04 ,  A61K31/196

CPC classification number: C07D471/04

Abstract: Disclosed are compounds of Formula (I):




or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US20230151007A1

公开(公告)日：2023-05-18

申请号：US17983097

申请日：2022-11-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Upender Velaparthi ,  Richard E. Olson ,  Chetan Padmakar Darne ,  Bireshwar Dasgupta ,  Jayakumar Sankara Warrier ,  Hasibur Rahaman ,  Prasada Rao Jalagam ,  Saumya Roy ,  Denise Christine Grunenfelder

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Disclosed are compounds of Formula (I):





or a salt thereof, wherein: R1, R2, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKξ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US20220324859A1

公开(公告)日：2022-10-13

申请号：US17164009

申请日：2021-02-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Upender Velaparthi ,  Louis S. Chupak ,  Chetan Padmakar Darne ,  Min Ding ,  Robert G. Gentles ,  Yazhong Huang ,  Manjunatha Narayana Rao Kamble ,  Scott W. Martin ,  Raju Mannoori ,  Ivar M. McDonald ,  Richard E. Olson ,  Hasibur Rahaman ,  Prasada Rao Jalagam ,  Saumya Roy ,  Gopikishan Tonukunuru ,  Sivasudar Velaiah ,  Jayakumar Sankara Warrier ,  Xiaofan Zheng ,  John S. Tokarski ,  Bireshwar Dasgupta ,  Kotha Rathnakar Reddy ,  Thiruvenkadam Raja

IPC: C07D471/04

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R3, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US11058767B2

公开(公告)日：2021-07-13

申请号：US16282138

申请日：2019-02-21

Applicant: Bristol-Myers Squibb Company ,  Roche Innovation Center Copenhagen A/S

Inventor： Richard E. Olson ,  Brian R. Anderson ,  Peter Hagedorn ,  Marianne Lerbech Jensen ,  Ivar M. McDonald ,  Stephen E. Mercer

IPC: C07H21/02 ,  C07H21/04 ,  A61K39/395 ,  A61K47/54 ,  A61K47/64 ,  A61K47/60 ,  A61P9/12 ,  A61P9/04 ,  A61K9/00 ,  C12N5/074 ,  C12N5/077 ,  C12N15/113 ,  A61K31/713 ,  A61K39/00

Abstract: The present disclosure relates to antisense oligonucleotides, which target CAMK2D mRNA in a cell, leading to reduced expression of CAMK2D protein. Reduction of CAMK2D protein expression is beneficial for the treatment of certain medical disorders, e.g., cardiovascular-related diseases or disorders.

公开(公告)号：US20210061802A1

公开(公告)日：2021-03-04

申请号：US17004058

申请日：2020-08-27

Applicant: Bristol-Myers Squibb Company

Inventor： Upender Velaparthi ,  Richard E. Olson ,  Chetan Padmakar Darne ,  Bireshwar Dasgupta ,  Jayakumar Sankara Warrier ,  Hasibur Rahaman ,  Prasada Rao Jalagam ,  Saumya Roy ,  Denise Christine Grunenfelder

IPC: C07D471/04

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US09708323B2

公开(公告)日：2017-07-18

申请号：US15317546

申请日：2015-06-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ivar M. McDonald ,  F. Christopher Zusi ,  Richard E. Olson

IPC: C07D471/18

CPC classification number: C07D471/18

Abstract: The disclosure provides compounds of formula I including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

公开(公告)号：US11964973B2

公开(公告)日：2024-04-23

申请号：US17130022

申请日：2020-12-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Robert G. Gentles ,  Upender Velaparthi ,  Min Ding ,  Richard E. Olson ,  Scott W. Martin ,  Saumya Roy ,  Prasada Rao Jalagam ,  Jayakumar Sankara Warrier ,  Louis S. Chupak ,  Denise Christine Grunenfelder

IPC: C07D471/04 ,  C07D401/04

CPC classification number: C07D471/04 ,  C07D401/04

Abstract: Disclosed are compounds of Formula (I):




or a salt thereof, wherein: X is CR6 or N; Y is CR3 or N; R1, R2, R3, R4, R5, R6, R7, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US20230118629A1

公开(公告)日：2023-04-20

申请号：US17785749

申请日：2020-12-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Upender Velaparthi ,  Chetan Padmakar Darne ,  Richard E. Olson ,  Jayakumar Sankara Warrier

IPC: C07D471/04 ,  A61P35/00 ,  C07D519/00

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: R1, R2, R4, R5, R6, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferatve disorders, such as cancer.

公开(公告)号：US20230086933A1

公开(公告)日：2023-03-23

申请号：US17785585

申请日：2020-12-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Upender Velaparthi ,  Chetan Padmakar Darne ,  Richard E. Olson ,  Prasada Rao Jalagam ,  Jayakumar Sankara Warrier

IPC: C07D471/04 ,  C07D519/00 ,  A61P35/00 ,  A61P31/12

Abstract: Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CR6 or N; Y is CR3 or N; R1, R2, R3, R4, R5, R6, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.